Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sino Biopharmaceutical ( (HK:1177) ) just unveiled an announcement.
Sino Biopharmaceutical Limited has proposed a final ordinary cash dividend of HKD 0.05 per share for the financial year ended 31 December 2025, with shareholder approval scheduled for 17 June 2026. The stock will trade ex-dividend on 24 June 2026, the record date is set for 2 July 2026, and eligible shareholders are expected to receive payment on 20 July 2026, signalling continued cash returns to investors and potential confidence in the company’s financial performance.
The dividend will be paid in Hong Kong dollars through the company’s Hong Kong share registrar, with no withholding tax or warrant or convertible security adjustments disclosed in connection with this payout. The board overseeing this decision consists of six executive directors and five independent non-executive directors, indicating a governance structure that combines family or founder leadership with independent oversight as the company maintains shareholder remuneration.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.90 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical company focused on the research, development, manufacturing, and sale of biopharmaceutical and chemical drugs. The group targets the China healthcare market with a portfolio that typically spans innovative therapies and generic medicines addressing major therapeutic areas.
Average Trading Volume: 65,606,412
Technical Sentiment Signal: Buy
Current Market Cap: HK$106.1B
See more insights into 1177 stock on TipRanks’ Stock Analysis page.